Cytogenetic testing of mutagenic and radioprotective effects of mesna.
The effects of mesna (sodium 2-mercaptoethane-sulfonate) on the frequency of sister chromatid exchange (SCE) and chromosomal aberrations were studied in PHA-stimulated lymphocytes in vitro. Our data give no evidence for either an increase of SCE or chromosomal aberrations and, thus, do not suggest a mutagenic or cancerogenic potential of this drug, when used clinically for the reduction of urotoxicity caused by oxazaphosphorine derivatives in cancer therapy. The possibility of a radioprotective effect of mesna could not be supported by the results obtained in this test system. However, there remained a slight comutagenic effect of mesna, if used together with irradiation, which should be taken into account when this drug is administered in the preparation of patients for bone marrow transplantation.
D002869:Chromosome Aberrations; D003434:Crossing Over, Genetic / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical; D005720:Gamma Rays; D006801:Humans; D066298:In Vitro Techniques; D007938:Leukemia / Q000628:therapy; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000187:drug effects* / Q000528:radiation effects / Q000648:ultrastructure; D008623:Mercaptoethanol / Q000031:analogs & derivatives*; D015080:Mesna / Q000378:metabolism / Q000494:pharmacology*; D011837:Radiation-Protective Agents; D012854:Sister Chromatid Exchange / Q000187:drug effects*
D011837:Radiation-Protective Agents; D008623:Mercaptoethanol; D015080:Mesna